Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00930683
Other study ID # MI-CP180
Secondary ID
Status Completed
Phase Phase 1
First received June 29, 2009
Last updated May 7, 2012
Start date September 2009
Est. completion date July 2011

Study information

Verified date May 2012
Source MedImmune LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.


Description:

The primary objective of this study is to evaluate the safety and tolerability of single and multiple IV doses of MEDI-546 in adult subjects with scleroderma who have skin thickening in an area suitable for repeat biopsy.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date July 2011
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female subjects = 18 years of age at the time of the first dose of MEDI-546;

- Written informed consent and HIPAA authorization (applies to covered entities in the US only) obtained from the subject or subject's legal representative;

- Must fulfill the American Rheumatism Association (American College of Rheumatology) preliminary classification criteria for systemic sclerosis;

- Has at least moderate skin thickening (score of at least 2 by modified Rodnan Total Skin Score [mRTSS]) in at least one area suitable for repeat biopsy, such as arms, legs, or trunk;

- Women, unless surgically sterile (including tubal ligation) or at least 2 years post-menopausal, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal, or implanted contraceptives, intrauterine device, diaphragm with spermicide, cervical cap, abstinence, and sterile sexual partner) in addition to the use of condoms (male or female condoms with spermicide) from signing of the informed consent through the end of the study. Cessation of birth control after this point should be discussed with a responsible physician. Men, unless surgically sterile, must likewise practice 2 effective methods of birth control (condom with spermicide or abstinence) and must use such precautions from Study Day 0 through the end of the study;

- Ability to complete the study period, including follow-up period through a maximum of Study Day 105; and

- Willing to forego other forms of experimental treatment during study.

Exclusion Criteria:

- History of allergy or reaction to any component of the MEDI-546 formulation;

- Forced vital capacity (FVC) < 60% predicted, diffusing capacity for carbon monoxide (DLCO) < 40% predicted, pulmonary hypertension requiring treatment with endothelin receptor antagonists or prostacyclin analogues, scleroderma renal crisis within the last year, or medically significant malabsorption;

- Have received the following medications within 28 days before entry:

- Cyclophosphamide at any dose

- Systemic cyclosporine at any dose

- Thalidomide at any dose

- Hydroxychloroquine > 600 mg/day

- Mycophenolate mofetil > 3 g/day

- Methotrexate > 25 mg/week

- Azathioprine > 3 mg/kg/day;

- Have received leflunomide > 20 mg/day within 6 months before entry;

- Have received fluctuating doses of the following within 28 days before entry:

- Antimalarials

- Mycophenolate mofetil

- Methotrexate

- Leflunomide

- Azathioprine;

- Have received prednisone > 20 mg/day or in fluctuating doses within 14 days before entry;

- Have received fluctuating doses of nonsteroidal anti-inflammatory drugs (NSAIDs) within 14 days before entry;

- Treatment with any investigational drug therapy within 28 days before entry into the study, B cell-depleting therapies within 12 months before entry, or biologic therapies within 30 days or 5 half-lives of the biologic agent, whichever is longer, before entry into the study;

- In the investigator's opinion, evidence of clinically significant active infection, including ongoing, chronic infection, within 28 days before entry;

- A history of severe viral infection as judged by the investigators, including severe infections of either cytomegalovirus (CMV) or the herpes family such as disseminated herpes, herpes encephalitis, ophthalmic herpes;

- Herpes zoster infection within 3 months before entry;

- Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of testing at screening;

- Vaccination with live attenuated viruses within 28 days before entry;

- Pregnancy (women, unless surgically sterile or at least 2 years post-menopausal, must have a negative serum pregnancy test within 28 days before receiving MEDI-546 and a negative urine pregnancy test on days of MEDI-546 administration before receiving MEDI-546);

- Breastfeeding or lactating women;

- History of primary immunodeficiency;

- History of alcohol or drug abuse < 1 year prior to entry;

- History of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy > 1 year prior to entry;

- History of active tuberculosis (TB) infection or latent TB infection without completion of an appropriate course of treatment;

- Newly positive TB skin test (defined as a reaction = 10 mm in diameter if not on systemic immunosuppressive medication or = 5 mm if on systemic immunosuppressive medication) without concomitant prophylactic therapy;

- Elective surgery planned from the time of signing of the informed consent through end of study;

- At screening blood tests (within 28 days before entry), any of the following:

- Aspartate aminotransferase (AST) > 2.5 x upper limit of the normal range (ULN), unless due to Myositis

- Alanine aminotransferase (ALT) > 2.5 x ULN

- Creatinine > 4.0 mg/dL

- Creatinine > 4.0 mg/dL

- Neutrophils < 1,500/mm3

- Platelet count < 50,000/mm3;

- History of any disease, evidence of any current disease (other than scleroderma), any finding upon physical examination, chest x-ray, or any laboratory abnormality that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study; or

- Any employee of the research site who is involved with the conduct of the study.

- History of vasculitis.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
MEDI-546
0.1 mg/kg MEDI-546 as a single IV dose
MEDI-546
0.3 mg/kg MEDI-546 as a single IV dose
MEDI-546
1.0 mg/kg MEDI-546 as a single IV dose
MEDI-546
3.0 mg/kg MEDI-546 as a single IV dose
MEDI-546
10.0 mg/kg MEDI-546 as a single IV dose
MEDI-546
0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
MEDI-546
1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
MEDI-546
5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
MEDI-546
20.0 mg/kg MEDI-546 as a single IV dose

Locations

Country Name City State
United States Research Site Ann Arbor Michigan
United States Boston University Boston Massachusetts
United States Metroplex Clinical Research Center Dallas Texas
United States Research Site Houston Texas
United States Research Site Lake Success New York
United States Research Site Los Angeles California
United States Research Site New Brunswick New Jersey
United States Research Site Salt Lake City Utah
United States University of Utah Medical Center Salt Lake City Utah
United States Research Site Seattle Washington
United States Research Site Toledo Ohio

Sponsors (1)

Lead Sponsor Collaborator
MedImmune LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The safety and tolerability of MEDI-546 will be assessed primarily by summarizing treatment-emergent AEs and SAEs. Study Day 84 for single-dose; Study Day 105 for multi-dose Yes
Secondary The secondary endpoints of the study are to assess the PK, IM, and PD of single and multiple IV doses of MEDI-546 in adult subjects with scleroderma. Study Day 84 for single-dose; Study Day 105 for multi-dose No
See also
  Status Clinical Trial Phase
Completed NCT02798055 - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed NCT01959815 - Novel Screening Strategies for Scleroderma PAH
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT02915835 - Riociguat in Scleroderma Associated Digital Ulcers Phase 2
Active, not recruiting NCT01895244 - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis Phase 2
Completed NCT00883129 - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) Phase 2
Completed NCT00074568 - Scleroderma Registry
Recruiting NCT04797286 - Sildenafil for Early Pulmonary Vascular Disease in Scleroderma Phase 2
Completed NCT03222492 - Brentuximab Vedotin for Systemic Sclerosis Phase 1/Phase 2
Completed NCT03207997 - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients N/A
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A
Completed NCT05080738 - Upper Extremity Home Exercises in Patients With Scleroderma N/A
Recruiting NCT03726398 - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH Phase 2/Phase 3
Recruiting NCT05085444 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma Early Phase 1
Completed NCT02062125 - Calcinosis in a Single-Center Scleroderma Population
Completed NCT04588714 - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT02835196 - Optical Elastography of Systemic Sclerosis Skin
Completed NCT02896205 - Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease Phase 3